Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

NCT ID: NCT07081607

Last Updated: 2025-07-23

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-07-15
• Study Completion Date: 2028-07-16

Brief Summary

In decades, the outcome of patients with peripherial T-cell lymphomas is dismal, especially in relapsed or refractory population. After failure to the frontline treatment, patients have limited treatment options and elderly population usually have no chance to undergo transplantation due to age or comorbidity, etc. Golidocitinib and chidamide were approved in treating r/r PTCL in China, while azacytidine has been demonstrated its anti-tumor activity in PTCL as well.

This study aims to explore the efficacy and safety of golidocitinib combined with azacytidine and chidamide in the patients with peripheral T-cell lymphoma who are eligible for intensive chemotherapy or transplantation.

Conditions

Peripheral T-Cell Lymphoma, Not Classified

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

golidocitinib with azacytidine and chidamide

Group Type: EXPERIMENTAL

golidocitinib with azacytidine and chidamide

Intervention Type: DRUG

In Phase I, a "3+3" dose-escalation design will be adopted to enroll 3 to 12 participants, exploring the recommended Phase II dose (RP2D) at two dose levels of golidocitinib: 150 mg every other day (QOD) and 150 mg once daily (QD).

In Phase II, we aim to evaluate the efficacy and safety of golidocitinib RP2D po in combination with chidamide 20mg biw po and azacytidine 100mg d1-7, SC in patients with peripheral T-cell lymphoma

Interventions

golidocitinib with azacytidine and chidamide

In Phase I, a "3+3" dose-escalation design will be adopted to enroll 3 to 12 participants, exploring the recommended Phase II dose (RP2D) at two dose levels of golidocitinib: 150 mg every other day (QOD) and 150 mg once daily (QD).

In Phase II, we aim to evaluate the efficacy and safety of golidocitinib RP2D po in combination with chidamide 20mg biw po and azacytidine 100mg d1-7, SC in patients with peripheral T-cell lymphoma

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Histopathologically confirmed peripheral T-cell lymphoma;

2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2;

3. Expected survival of ≥12 weeks;

4. Measurable disease lesions;

5. Any conditions considered ineligible for intenvive chemotherapy, including but not limted to age > 60 years, at least one comorbidity scored 3 points, or more than 4 comorbidities scored 2 points each according to the CIRS scale;

6. Female participants of childbearing potential and male participants with partners of childbearing potential must agree to and adhere to effective contraceptive measures during the treatment period and for 180 days after the last dose of the study drug;

7. Participants must voluntarily join the study, sign the informed consent form, demonstrate good compliance, and cooperate with follow-up assessments.

Exclusion Criteria

1. Involvement of the central nervous system (CNS);

2. History of malignancies except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix;

3. Uncontrolled cardio- and cerebro-vascular disease, blood clotting disorders, connective tissue diseases, serious infectious diseases and other diseases

4. Left ventricular ejection fraction<50%

5. Laboratory measures meet the following criteria at screening (unless caused by lymphoma):

• Neutrophils<1.5×10^9/L
• Platelets<75×10^9/L (Platelets<50×10^9/L in case of bone marrow involvement)
• ALT or AST is 2 times higher than the upper limits of normal (ULN), AKP and bilirubin are 1.5 times higher than the ULN.
• Creatinine is 1.5 times higher than the ULN.

6. HIV-infected patients

7. Patients with psychiatric disorders or patients who are known or suspected to be unable to fully comply with the study protocol

8. Pregnant or lactation

9. Require treatment with strong/moderate CYP3A inhibitors or inducers.

10. Inability to swallow capsules or presence of diseases that significantly affect gastrointestinal function, such as malabsorption syndrome, post-bariatric surgery, inflammatory bowel disease and complete or incomplete intestinal obstruction

11. Other medical conditions determined by the researchers that may affect the study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ruijin Hospital

OTHER

Sponsor Role: lead

Responsible Party

Zhao Weili

Professor and Director，Shanghai Institute of Hematology

Responsibility Role: PRINCIPAL_INVESTIGATOR

Central Contacts

Wang Li

Role: CONTACT

zwl_trial@163.com

+86 02164370045

Other Identifiers

PTCL-chemofree

Identifier Type: -

Identifier Source: org_study_id